Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
ACCESSWIRE
Up to 2,178% more CBD delivered into bloodstream*
Up to 1,737% more CBD delivered into brain tissue*
KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs.
Study HYPER-A21-1 included three new 'DehydraTECH 2.0' formulation variations designed to enable cannabidiol ('CBD') delivery performance enhancements and pharmacokinetic optimization. All three new DehydraTECH 2.0 formulations delivered improved performance when compared to both Lexaria's original DehdyraTECH 1.0 and 2.0 concentration-matched formulations, as well as to a medium chain triglyceride ('MCT') oil based control formulation representative of standard industry practices Summary data is shown below: